DeepMed Research

Trastuzumab Rezetecan

Generic Name: Trastuzumab Rezetecan

Clinical Trials

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer with Brain Metastases

Phase 2

Recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: SHR-A1811
Drug: Pyrotinib
Drug: Bevacizumab

First Posted Date: 2023-03-15

Last Posted Date: 2024-10-09

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 125

Registration Number: NCT05769010

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Phase 2

Recruiting

Conditions: HER2-positive Breast Cancer

Interventions: Drug: SHR-A1811
Drug: Pyrotinib

First Posted Date: 2022-12-02

Last Posted Date: 2024-07-05

Lead Sponsor: Shengjing Hospital

Target Recruit Count: 65

Registration Number: NCT05635487

Locations: 🇨🇳
Shengjing Hospital affiliated to China Medical University, Shenyang, Liaoning, China

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Phase 2

Recruiting

Conditions: HER2-negative Breast Cancer
Advanced Breast Cancer
Breast Neoplasm
Breast Cancer
Hormone Receptor Positive Tumor

Interventions: Drug: PIK3CA inhibitor
Drug: AKT inhibitor
Drug: SHR-A1811
Drug: Carrelizumab
Drug: SHR-1167
Drug: Famitinib
Drug: Sorafenib
Drug: Everolimus
Drug: Fluzoparib
Drug: Aromatase Inhibitors or Fulvestrant
Drug: TPC
Drug: SHR-A1921
Drug: SHR-6209
Drug: Dalpiciclib
Drug: Apatinib
Drug: SHR-A2009
Drug: SHR-A2102
Drug: Goserelin
Drug: bevacizumab

First Posted Date: 2022-10-26

Last Posted Date: 2024-10-04

Lead Sponsor: Fudan University

Target Recruit Count: 620

Registration Number: NCT05594095

Locations: 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Phase 2

Recruiting

Conditions: Breast Neoplasm
HER2-positive Breast Cancer
HER2-negative Breast Cancer
Hormone Receptor Positive Tumor
Breast Cancer
Breast Tumors
Hormone Receptor Negative Tumor
Triple-Negative Breast Cancer (TNBC)
Locally Advanced Breast Cancer
Early-stage Breast Cancer

Interventions: Drug: Nab paclitaxel
Drug: Camrelizumab
Drug: Pyrotinib
Drug: SHR-A1811
Drug: SHR-A1921
Drug: Pertuzumab
Drug: SHR-1316
Drug: Dalpiciclib
Drug: Trastuzumab
Drug: Goserelin
Drug: Carboplatin
Drug: Apatinib
Drug: Letrozole
Drug: Famitinib
Drug: Epirubicin
Drug: Cyclophosphamide
Drug: Fluzoparib

First Posted Date: 2022-10-17

Last Posted Date: 2024-12-27

Lead Sponsor: Fudan University

Target Recruit Count: 716

Registration Number: NCT05582499

Locations: 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China

A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

Phase 3

Recruiting

Conditions: HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

Interventions: Drug: Pyrotinib in combination with Capecitabine.
Drug: SHR-A1811

First Posted Date: 2022-06-21

Last Posted Date: 2022-08-10

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 269

Registration Number: NCT05424835

Locations: 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China

A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers

Phase 2

Conditions: Advanced Solid Tumors

Interventions: Drug: SHR-A1811
Drug: Fluzoparib Capsule

First Posted Date: 2022-04-27

Last Posted Date: 2022-06-30

Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Target Recruit Count: 212

Registration Number: NCT05349409

Locations: 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China

A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Advanced Non-small Cell Lung Cancer

Interventions: Drug: SHR-A1811

First Posted Date: 2021-03-26

Last Posted Date: 2024-06-13

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 157

Registration Number: NCT04818333

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors

Phase 1

Active, not recruiting

Conditions: Gastric Cancer
Colorectal Cancer

Interventions: Drug: SHR-A1811

First Posted Date: 2020-08-14

Last Posted Date: 2024-03-20

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 101

Registration Number: NCT04513223

Locations: 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China

A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: SHR-A1811

First Posted Date: 2020-06-24

Last Posted Date: 2023-07-21

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 226

Registration Number: NCT04446260

Locations: 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇦🇺
Macquarie University Hospital, Macquarie, New South Wales, Australia

and more 32 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy